Literature DB >> 32603290

Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic Neonates, Children, and Adolescents.

Arnaud G L'Huillier, Giulia Torriani, Fiona Pigny, Laurent Kaiser, Isabella Eckerle.   

Abstract

Children do not seem to drive transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We isolated culture-competent virus in vitro from 12 (52%) of 23 SARS-CoV-2-infected children; the youngest was 7 days old. Our findings show that symptomatic neonates, children, and teenagers shed infectious SARS-CoV-2, suggesting that transmission from them is plausible.

Entities:  

Keywords:  2019 novel coronavirus disease; COVID-19; SARS-CoV-2; Switzerland; adolescents; children; coronavirus disease; neonates; respiratory diseases; severe acute respiratory syndrome coronavirus 2; viral shedding; viruses; zoonoses

Mesh:

Substances:

Year:  2020        PMID: 32603290      PMCID: PMC7510703          DOI: 10.3201/eid2610.202403

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Children are underrepresented in coronavirus disease (COVID-19) case numbers (,). Severity in most children is limited, and children do not seem to be major drivers of transmission (,). However, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects children of all ages (,). Despite the high proportion of mild or asymptomatic infections (), they should be considered as transmitters unless proven otherwise. To address this point, the laboratory of the Geneva University Hospitals and Faculty of Medicine, University of Geneva (Geneva, Switzerland), used cell culture to systematically assess cultivable SARS-CoV-2 in the upper respiratory tract (URT) of 23 children with COVID-19. All nasopharyngeal specimens (NPS) were collected with a flocked swab in universal transport medium (Floqswab; Copan, https://www.copangroup.com) and tested for SARS-CoV-2 by reverse transcription PCR during January 25–March 31, 2020 (Appendix). We seeded Vero E6 cells at 8 × 104 cells/well in a 24-well plate and inoculated them with 200 μL of viral transport medium the following day. Cells were inoculated for 1 h at 37°C; inoculum was removed; cells were washed once with phosphate buffered saline; and regular cell growth medium containing 10% fetal calf serum was added. We observed cells on days 2, 4, and 6 for cytopathic effect (CPE) by light microscopy. We harvested supernatant at first observation of CPE or, if no CPE occurred, on day 6. For a second passage, we transferred 20 μL supernatant of CPE-positive specimens onto new Vero E6 cells. We collected supernatant after inoculation and on observation of CPE and confirmed isolation of replication competent SARS-CoV-2 by an increase in viral RNA (Appendix). Of 638 patients <16 years of age, 23 (3.6%) tested positive for SARS-CoV-2. Median age was 12.0 years (interquartile range [IQR] 3.8–14.5 years, range 7 days–15.9 years). Thirteen patients had an URT infection; 2 each had fever without source and pneumonia (Table). Samples were collected a median of 2 (IQR 1–3) days after symptom onset. Median viral RNA load at diagnosis was 3.0 × 106 copies/mL (mean 4.4 × 108 [IQR 6.9 × 103–4.4 × 108] copies/mL; peak 5.3 × 109 copies/mL).
Table

Characteristics and results of children <16 years of age with coronavirus disease, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Switzerland, January 25–March 31, 2020*

PatientAgeDays from symptom onset to diagnosisClinical diagnosisHospital admissionViral RNA copies/mLIsolate
112.6 y1URTINo2.8 × 107Negative
25.7 y1URTINo1.8 × 106Negative
314.8 y1URTINo9.9 × 106Positive
412.0 y2Obstructive bronchitisNo6.9 × 103Negative
53.9 y4URTINo4.5 × 103Negative
613.9 y2PneumoniaYes8.6 × 107Positive
79.0 y2CroupNo6.2 × 103Negative
810.1 y3URTINo3.3 × 105Negative
93 moNot reportedNot reportedYes2.8 × 102Negative
102.2 yNot reportedNot reportedYes5.9 × 102Negative
118.4 y1URTINo5.6 × 108Negative
127 d1URTINo1.3 × 108Positive
1312.9 y4PneumoniaYes4.2 × 103Negative
1415.7 yNot reportedNot reportedNo2.5 × 104Negative
1512.3 y2Influenza-like illnessNo1.1 × 109Positive
1615.9 y1Fever without sourceYes2.2 × 108Positive
171 mo0Fever without sourceYes5.3 × 109Positive
182 mo1URTINo4.4 × 108Positive
195.9 y1URTINo1.6 × 109Positive
2015.9 y2URTINo6.8 × 108Positive
2114.4 y5URTIYes1.4 × 105Positive
2214.6 y3URTINo1.2 × 104Positive
2314.4 y2URTINo3.0 × 106Positive

*URTI, upper respiratory tract infection.

*URTI, upper respiratory tract infection. We isolated SARS-CoV-2 from 12 (52%) children. We determined SARS-CoV-2 isolation by presence of CPE and increased viral RNA in the supernatant (Table; Appendix Figure). SARS-CoV-2 replication in all 12 positive isolates was confirmed by a second passage. We isolated virus from children of all ages; the youngest was 7 days of age. Median viral load was higher for patients with isolation (1.7 × 108 [mean 7.9 × 108, IQR 4.7 × 106–1.0 × 109] copies/mL) than for those without isolation (6.9 × 103 [mean 5.4 × 107, IQR 4.2 × 103–1.8 × 106] copies/mL; p = 0.002) (Figure). Sex, age, duration of symptoms, clinical diagnosis, symptoms, and likelihood of admission did not differ between patients with and without isolation (Appendix Table).
Figure

Severe acute respiratory syndrome coronavirus 2 initial RNA copy numbers from nasopharyngeal swabs of culture-negative and culture-positive specimens from children <16 years of age, Geneva University Hospitals, Geneva, Switzerland, January 25–March 31, 2020. Thick horizontal bars indicate median RNA; thin horizontal bars indicate interquartile range. Asterisk (*) indicates specimen collected outside the institution, suggesting a longer time to freezing at –80°C; dagger (†) indicates specimen with ≈48 hours from specimen collection to freezing at –80°C.

Severe acute respiratory syndrome coronavirus 2 initial RNA copy numbers from nasopharyngeal swabs of culture-negative and culture-positive specimens from children <16 years of age, Geneva University Hospitals, Geneva, Switzerland, January 25–March 31, 2020. Thick horizontal bars indicate median RNA; thin horizontal bars indicate interquartile range. Asterisk (*) indicates specimen collected outside the institution, suggesting a longer time to freezing at –80°C; dagger (†) indicates specimen with ≈48 hours from specimen collection to freezing at –80°C. Our data show that viral load at diagnosis is comparable to that of adults (,) and that symptomatic children of all ages shed infectious virus in early acute illness, a prerequisite for further transmission. Isolation of infectious virus was largely comparable with that of adults, although 2 specimens yielded an isolate at lower viral load (1.2 × 104 and 1.4 × 105 copies/mL) (). A limitation of our study was the small number of children assessed. However, although the Canton of Geneva was a region severely affected by SARS-CoV-2 (), only 23 cases were diagnosed in children at our hospital during the study period. These findings confirm that children are not a major risk group for COVID-19. Another limitation is our reliance solely on leftover material initially received for routine diagnostic purposes that we retrospectively analyzed. Using such specimens has several disadvantages: preanalytic quality of specimens could be affected by suboptimal times between sample collection and storage at −80°C because of transport and diagnostic processing time, resulting in loss in infectivity and failure of virus isolation even in the presence of high viral load. Therefore, our findings probably underestimate the true rate of infectious virus presence in symptomatic children, and we cannot comment whether our data reflect the rates of infectious virus shedding in the community. Because of the limited leftover volume of the specimens, we were unable to further investigate the quantity of infectious viral particles. Most patients were managed as outpatients and self-isolated at home, so no consecutive sampling was possible to assess infectious virus in multiple samples over the course of disease. SARS-CoV-2 viral load and shedding patterns of culture-competent virus in 12 symptomatic children resemble those in adults. Therefore, transmission of SARS-CoV-2 from children is plausible. Considering the relatively low frequency of infected children, even in severely affected areas, biological or other unknown factors could lead to the lower transmission in this population. Large serologic investigations and systematic surveillance for acute respiratory diseases and asymptomatic presentations are needed to assess the role of children in this pandemic.

Appendix

Additional methods for a study of SARS-CoV-2 in symptomatic neonates, children, and adolescents.
  6 in total

1.  Coronavirus Disease 2019 (COVID-19) in Italy.

Authors:  Edward Livingston; Karen Bucher
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  Virological assessment of hospitalized patients with COVID-2019.

Authors:  Roman Wölfel; Victor M Corman; Wolfgang Guggemos; Michael Seilmaier; Sabine Zange; Marcel A Müller; Daniela Niemeyer; Terry C Jones; Patrick Vollmar; Camilla Rothe; Michael Hoelscher; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Rosina Ehmann; Katrin Zwirglmaier; Christian Drosten; Clemens Wendtner
Journal:  Nature       Date:  2020-04-01       Impact factor: 49.962

3.  Children with Covid-19 in Pediatric Emergency Departments in Italy.

Authors:  Niccolò Parri; Matteo Lenge; Danilo Buonsenso
Journal:  N Engl J Med       Date:  2020-05-01       Impact factor: 91.245

4.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.

Authors:  Silvia Stringhini; Ania Wisniak; Giovanni Piumatti; Andrew S Azman; Stephen A Lauer; Hélène Baysson; David De Ridder; Dusan Petrovic; Stephanie Schrempft; Kailing Marcus; Sabine Yerly; Isabelle Arm Vernez; Olivia Keiser; Samia Hurst; Klara M Posfay-Barbe; Didier Trono; Didier Pittet; Laurent Gétaz; François Chappuis; Isabella Eckerle; Nicolas Vuilleumier; Benjamin Meyer; Antoine Flahault; Laurent Kaiser; Idris Guessous
Journal:  Lancet       Date:  2020-06-11       Impact factor: 79.321

5.  SARS-CoV-2 Infection in Children.

Authors:  Xiaoxia Lu; Liqiong Zhang; Hui Du; Jingjing Zhang; Yuan Y Li; Jingyu Qu; Wenxin Zhang; Youjie Wang; Shuangshuang Bao; Ying Li; Chuansha Wu; Hongxiu Liu; Di Liu; Jianbo Shao; Xuehua Peng; Yonghong Yang; Zhisheng Liu; Yun Xiang; Furong Zhang; Rona M Silva; Kent E Pinkerton; Kunling Shen; Han Xiao; Shunqing Xu; Gary W K Wong
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

6.  Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.

Authors:  Haiyan Qiu; Junhua Wu; Liang Hong; Yunling Luo; Qifa Song; Dong Chen
Journal:  Lancet Infect Dis       Date:  2020-03-25       Impact factor: 71.421

  6 in total
  47 in total

1.  Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus.

Authors:  Stephen Poole; Nathan J Brendish; Alex R Tanner; Tristan W Clark
Journal:  Lancet Respir Med       Date:  2020-10-22       Impact factor: 30.700

Review 2.  Transmission of SARS-CoV-2 by Children.

Authors:  Joanna Merckx; Jeremy A Labrecque; Jay S Kaufman
Journal:  Dtsch Arztebl Int       Date:  2020-08-17       Impact factor: 5.594

3.  Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19).

Authors:  Taylor Heald-Sargent; William J Muller; Xiaotian Zheng; Jason Rippe; Ami B Patel; Larry K Kociolek
Journal:  JAMA Pediatr       Date:  2020-09-01       Impact factor: 16.193

4.  Virological Characteristics of Hospitalized Children With SARS-CoV-2 Infection.

Authors:  Swetha G Pinninti; Sunil Pati; Claudette Poole; Misty Latting; Maria C Seleme; April Yarbrough; Nitin Arora; William J Britt; Suresh Boppana
Journal:  Pediatrics       Date:  2021-02-23       Impact factor: 7.124

Review 5.  Challenges and Issues of Anti-SARS-CoV-2 Vaccines.

Authors:  Sophie Blumental; Patrice Debré
Journal:  Front Med (Lausanne)       Date:  2021-05-14

6.  Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown.

Authors:  Marie-Kathrin Breyer; Robab Breyer-Kohansal; Sylvia Hartl; Michael Kundi; Lukas Weseslindtner; Karin Stiasny; Elisabeth Puchhammer-Stöckl; Andrea Schrott; Manuela Födinger; Michael Binder; Markus Fiedler; Emiel F M Wouters; Otto C Burghuber
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

7.  SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020.

Authors:  Arnaud Fontanet; Laura Tondeur; Rebecca Grant; Sarah Temmam; Yoann Madec; Thomas Bigot; Ludivine Grzelak; Isabelle Cailleau; Camille Besombes; Marie-Noëlle Ungeheuer; Charlotte Renaudat; Blanca Liliana Perlaza; Laurence Arowas; Nathalie Jolly; Sandrine Fernandes Pellerin; Lucie Kuhmel; Isabelle Staropoli; Christèle Huon; Kuang-Yu Chen; Bernadette Crescenzo-Chaigne; Sandie Munier; Pierre Charneau; Caroline Demeret; Timothée Bruel; Marc Eloit; Olivier Schwartz; Bruno Hoen
Journal:  Euro Surveill       Date:  2021-04

Review 8.  The use of pediatric flexible bronchoscopy in the COVID-19 pandemic era.

Authors:  Domenico Paolo La Regina; Raffaella Nenna; Dirk Schramm; Nadine Freitag; Pierre Goussard; Ernst Eber; Fabio Midulla
Journal:  Pediatr Pulmonol       Date:  2021-03-17

9. 

Authors:  Jared Bullard; Duane Funk; Kerry Dust; Lauren Garnett; Kaylie Tran; Alex Bello; James E Strong; Santina J Lee; Jillian Waruk; Adam Hedley; David Alexander; Paul Van Caeseele; Carla Loeppky; Guillaume Poliquin
Journal:  CMAJ       Date:  2021-06-07       Impact factor: 8.262

10.  Children's role in the COVID-19 pandemic: a systematic review of early surveillance data on susceptibility, severity, and transmissibility.

Authors:  Katy A M Gaythorpe; Sangeeta Bhatia; Tara Mangal; H Juliette T Unwin; Natsuko Imai; Gina Cuomo-Dannenburg; Caroline E Walters; Elita Jauneikaite; Helena Bayley; Mara D Kont; Andria Mousa; Lilith K Whittles; Steven Riley; Neil M Ferguson
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.